Bradshaw's brand of pulse-pounding, mind-bending mystery/thrillers draw upon his unique combination of professional skills as a Forensic Investigator, Medical Business Executive, and innovative Biotechnology Entrepreneur. Whether he is standing over a homicide victim at a macabre crime scene or in a boardroom with unbridled power and wealth, Bradshaw has navigated real danger by knowing the unbelievable is possible and evil walks among us. Today he takes his audience into the utterly plausible realms of mystery and suspense where true danger lingers, real monsters exist, and the battles between good and evil endure.
Bradshaw received his BA at the University of Texas and Forensic Investigation training at the Institute of Forensic Sciences in Dallas where he investigated 3,000 cases for the Medical Examiners. At a young age he controlled horrific death scenes for the 14th largest city in the country and worked with the ME to determine cause and manner of death (homicide, suicide, accidental). His Biomedical Business career began at (BD) Becton Dickenson and flourished at (DCW) Dow Corning Corporation where he contributed to the evolution of healthcare worldwide. As the Founder, President/CEO of Biotech startups Bradshaw raised $25 million and led the development of game-changing biotechnology opening early-intervention, minimal-invasive medical device markets worldwide.
Today seven STEVE BRADSHAW novels are available in softcover, eBooks, and audiobook (Amazon, Barnes & Noble, Google Play, KOBO) and the release of KAYDA in 2026 and KHAOS in 2027. The author often does book-signings and speaking events upon request: use CONTACT page on this website to schedule the author.
Release of Bradshaw's first screenplay, TERMINAL BREACH. Now open for agent/partner inquiries to explore taking this creation into Movie and/or TV Series markets in 2026. Time limited. Please reach out to author today. Initial connection via the CONTACT PAGE on this website.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.